Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As MS Space Awaits Ocrevus, MedDay Sees 'Synergistic' Positioning Opportunity

Executive Summary

With Roche's Ocrevus expected to be given the green light at any moment for the underserved progressive multiple sclerosis market, a tiny French biotech with a "synergistic" product for the same indication also believes it could soon have a commercial success on its hands.

You may also be interested in...



Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy

Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.

MedDay Raises €34m For US Trial As EU Filing Of MS Drug Nears

MedDay of France, which is preparing a European filing for its progressive multiple sclerosis product MD1003, has raised €34m in a Series B financing round. Edmond de Rothschild Investment Partners (EDRIP) led the new investment round alongside existing investors Sofinnova Partners, the company's largest shareholder, and InnoBio (Bpifrance). Large Venture (Bpifrance) also participated.

Phase III success in progressive multiple sclerosis

The last couple of decades have seen major progress in the treatment of relapsing-remitting multiple sclerosis (RRMS), with a number of drug approvals. In contrast, clinical trials of drug candidates in progressive multiple sclerosis have failed to deliver the same successes. However, a small French biotech company believes it can change all this with its high-dose biotin product.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel